Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: PROTEOMICS IN DIAGNOSTICS
Article type: Research Article
Authors: Bergen, III, H. Robert; | Vasmatzis, George | Cliby, William A. | Johnson, Kenneth L.; | Oberg, Ann L. | Muddiman, David C.;
Affiliations: W.M. Keck FT-ICR Mass Spectrometry Laboratory, Mayo Proteomics Research Center, Rochester, MN, USA | Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA | Division of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA | Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN, USA | Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Note: [] Corresponding author: David C. Muddiman, Ph.D., Medical Science Building 3-115, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA. Tel.: +1 507 284 1997; Fax: +1 507 284 9261; E-mail: muddiman.david@mayo.edu
Abstract: Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/IV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.
Keywords: ovarian cancer, biomarkers, bioinformatics, serum, FT-ICR, TOF, mass spectrometry
Journal: Disease Markers, vol. 19, no. 4-5, pp. 239-249, 2003,2004
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl